Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has experienced a decline in its stock price by -1.76 compared to its previous closing price of 51.61. However, the company has seen a gain of 7.69% in its stock price over the last five trading days. GlobeNewsWire reported 2024-02-27 that 44 th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26 th Annual Global Healthcare Conference on March 13 NOVATO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that management will be participating in three upcoming investor conferences.
Is It Worth Investing in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Right Now?
Company’s 36-month beta value is 0.64.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 6 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for RARE is 77.02M, and currently, short sellers hold a 5.09% ratio of that floaft. The average trading volume of RARE on April 12, 2024 was 728.51K shares.
RARE’s Market Performance
RARE’s stock has seen a 7.69% increase for the week, with a 6.38% rise in the past month and a 7.51% gain in the past quarter. The volatility ratio for the week is 5.19%, and the volatility levels for the past 30 days are at 3.63% for Ultragenyx Pharmaceutical Inc. The simple moving average for the past 20 days is 6.69% for RARE’s stock, with a 20.08% simple moving average for the past 200 days.
Analysts’ Opinion of RARE
Many brokerage firms have already submitted their reports for RARE stocks, with Wells Fargo repeating the rating for RARE by listing it as a “Overweight.” The predicted price for RARE in the upcoming period, according to Wells Fargo is $72 based on the research report published on December 08, 2023 of the previous year 2023.
Credit Suisse, on the other hand, stated in their research note that they expect to see RARE reach a price target of $96. The rating they have provided for RARE stocks is “Outperform” according to the report published on June 14th, 2023.
Evercore ISI gave a rating of “Outperform” to RARE, setting the target price at $80 in the report published on June 06th of the previous year.
RARE Trading at 5.81% from the 50-Day Moving Average
After a stumble in the market that brought RARE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.78% of loss for the given period.
Volatility was left at 3.63%, however, over the last 30 days, the volatility rate increased by 5.19%, as shares surge +4.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.97% upper at present.
During the last 5 trading sessions, RARE rose by +7.69%, which changed the moving average for the period of 200-days by +4.28% in comparison to the 20-day moving average, which settled at $47.63. In addition, Ultragenyx Pharmaceutical Inc. saw 6.02% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RARE starting from Kassberg Thomas Richard, who sale 11,509 shares at the price of $49.93 back on Mar 11 ’24. After this action, Kassberg Thomas Richard now owns 252,823 shares of Ultragenyx Pharmaceutical Inc., valued at $574,644 using the latest closing price.
Fust Matthew K, the Director of Ultragenyx Pharmaceutical Inc., sale 12,195 shares at $50.88 during a trade that took place back on Mar 07 ’24, which means that Fust Matthew K is holding 14,860 shares at $620,443 based on the most recent closing price.
Stock Fundamentals for RARE
Current profitability levels for the company are sitting at:
- -1.31 for the present operating margin
- 0.9 for the gross margin
The net margin for Ultragenyx Pharmaceutical Inc. stands at -1.4. The total capital return value is set at -0.47. Equity return is now at value -193.23, with -39.80 for asset returns.
Based on Ultragenyx Pharmaceutical Inc. (RARE), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -11.0. The debt to equity ratio resting at 0.16. The interest coverage ratio of the stock is -8.62.
Currently, EBITDA for the company is -516.85 million with net debt to EBITDA at 0.32. When we switch over and look at the enterprise to sales, we see a ratio of 9.22. The receivables turnover for the company is 5.92for trailing twelve months and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.61.
Conclusion
In a nutshell, Ultragenyx Pharmaceutical Inc. (RARE) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
